DFW Exits Vidara Therapeutics
Search
Share on twitter
Share on linkedin
Share on print
Share on email

DFW Exits Vidara Therapeutics

vidara nf1DFW Capital Partners has completed the previously announced sale of its portfolio company, Vidara Therapeutics, to Horizon Pharma, in a cash and stock transaction valued at approximately $587 million. DFW invested in Vidara in 2012 through its third private equity fund, DFW Capital Partners III, LP.

Vidara is a specialty pharmaceutical developer and marketer, focused on rare disease and niche therapies in the orphan drug arena (www.vidararx.com).  DFW originally invested in Vidara in 2012, to support the company’s acquisition of Actimmune, a patented biologic injectable form of interferon gamma-1b, approved for the treatment of chronic granulomatous disease which is a genetic disorder that affects the functioning of some cells of the immune system; and for the treatment of patients with severe, malignant osteopetrosis, a genetic disorder that affects normal bone formation.

Keith Pennell nf1“We are thrilled with the outstanding operational and financial success that Vidara’s team has accomplished in a relatively short period, and are equally excited to achieve both a successful financial exit and go-forward affiliation with Horizon and its talented management team,” said Keith Pennell, DFW’s Managing Partner.

DFW Capital Partners invests in lower middle market companies. Sectors of interest include outsourced healthcare and business services, including clinical services, specialty distribution, automated dispensing and pharmacy technology. DFW is headquartered in Teaneck, NJ, and maintains an office in Chevy Chase, MD (www.dfwcapital.com).

Lazard Middle Market represented Vidara and its shareholders on this transaction.

2014 PEPD • Private Equity’s Leading News Magazine • 9-22-14

Share on twitter
Share on linkedin
Share on print
Share on email

To search in site, type your keyword and hit enter